BRPI0912570A2 - anticorpos humanizados contra interferon-alfa humano - Google Patents
anticorpos humanizados contra interferon-alfa humanoInfo
- Publication number
- BRPI0912570A2 BRPI0912570A2 BRPI0912570A BRPI0912570A BRPI0912570A2 BR PI0912570 A2 BRPI0912570 A2 BR PI0912570A2 BR PI0912570 A BRPI0912570 A BR PI0912570A BR PI0912570 A BRPI0912570 A BR PI0912570A BR PI0912570 A2 BRPI0912570 A2 BR PI0912570A2
- Authority
- BR
- Brazil
- Prior art keywords
- humanized antibodies
- interferon alpha
- human interferon
- human
- alpha
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08103847 | 2008-05-07 | ||
EP08103847.3 | 2008-05-07 | ||
PCT/EP2009/055448 WO2009135861A2 (en) | 2008-05-07 | 2009-05-06 | Humanized antibodies against human interferon-alpha |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0912570A2 true BRPI0912570A2 (pt) | 2016-04-26 |
BRPI0912570B1 BRPI0912570B1 (pt) | 2021-04-06 |
BRPI0912570B8 BRPI0912570B8 (pt) | 2021-05-25 |
Family
ID=40901961
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0912570A BRPI0912570B8 (pt) | 2008-05-07 | 2009-05-06 | anticorpo anti-ifn-alfa humanizado, ou um fragmento de ligação ao antígeno do mesmo, composição terapêutica e seus usos |
Country Status (16)
Country | Link |
---|---|
US (3) | US8163885B2 (pt) |
EP (1) | EP2279207B1 (pt) |
JP (1) | JP5766598B2 (pt) |
KR (1) | KR101687032B1 (pt) |
CN (1) | CN102083859B (pt) |
AU (1) | AU2009245792B2 (pt) |
BR (1) | BRPI0912570B8 (pt) |
CA (1) | CA2722622C (pt) |
ES (1) | ES2549903T3 (pt) |
HK (1) | HK1154251A1 (pt) |
IL (1) | IL208979B (pt) |
MX (1) | MX2010012052A (pt) |
RU (1) | RU2532832C2 (pt) |
TW (1) | TWI453032B (pt) |
WO (1) | WO2009135861A2 (pt) |
ZA (1) | ZA201008748B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101363120B1 (ko) | 2005-02-10 | 2014-02-13 | 베일러 리서치 인스티튜트 | 항-인터페론 알파 모노클로날 항체 및 사용 방법 |
MX2013013785A (es) * | 2011-05-25 | 2014-07-28 | Medimmune Llc | Metodos para tratar lupus eritematoso sistemico, escleroderma y miositis con un anticuerpo contra el interferon alfa. |
WO2013034160A1 (en) * | 2011-09-06 | 2013-03-14 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. | Methods for analyzing biological macromolecular complexes and use thereof |
JP6466904B2 (ja) * | 2013-03-15 | 2019-02-06 | ヤンセン バイオテツク,インコーポレーテツド | インターフェロンアルファ及びオメガ抗体アンタゴニスト |
KR102402973B1 (ko) * | 2013-07-03 | 2022-05-27 | 이뮤노큐어 아게 | 인간 항-ifn-알파 항체 |
TWI713453B (zh) * | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
US10689703B2 (en) * | 2015-04-27 | 2020-06-23 | National Jewish Health | Methods of identifying and treating subjects having acute respiratory distress syndrome |
CN108204958A (zh) * | 2016-12-19 | 2018-06-26 | 伊缪泰普有限公司 | 结合测定 |
KR20220050168A (ko) * | 2019-08-19 | 2022-04-22 | 팬디온 오퍼레이션스, 인코포레이티드 | Pd-1 작용제로 표적된 면역관용 |
RU2737466C1 (ru) * | 2019-12-30 | 2020-11-30 | Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) | Гуманизированное нейтрализующее антитело к интерферону-бета человека |
CN112500476B (zh) * | 2020-12-16 | 2024-02-23 | 南京基蛋生物医药有限公司 | 一种扩增鼠单抗重轻链基因序列的方法及其引物和筛选该引物的方法 |
CN116355079B (zh) * | 2022-08-19 | 2023-12-26 | 上海迈科康生物科技有限公司 | 检测重组人轮状病毒vp8抗原(vp8 p[8])的单克隆抗体及其应用 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4423147A (en) | 1980-04-11 | 1983-12-27 | Secher David S | Monoclonal antibody to interferon-α |
US4605394A (en) | 1982-12-03 | 1986-08-12 | Simon V. Skurkovich | Methods for the treatment of pathological conditions by removing interferon from the organism |
US4362155A (en) | 1981-03-24 | 1982-12-07 | Skurkovich Simon V | Method and apparatus for the treatment of autoimmune and allergic diseases |
US4824432A (en) | 1981-03-24 | 1989-04-25 | S.V.S. Laboratories, Inc. | Method for treating AIDS and other immune deficiencies and immune disorders |
DE3211263A1 (de) | 1981-03-31 | 1983-01-27 | Otsuka Pharmaceutical Co. Ltd., Tokyo | Human-interferon verwandte peptide, antigene und antikoerper, sowie verfahren zu deren herstellung |
EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
FR2560212B1 (fr) | 1984-02-24 | 1989-12-29 | Unicet | Anticorps monoclonaux contre l'interferon a2 et hybridomes produisant de tels anticorps |
CA2085469C (fr) | 1991-04-17 | 2007-07-31 | Pierre Eid | Polypeptides hydrosolubles ayant une haute affinite pour les interferons .alpha. et .beta. |
DK0601052T3 (da) | 1991-08-30 | 1996-11-18 | Genentech Inc | Terapeutisk fremgangsmåde til behandling af IDDM |
EP0563487A1 (en) | 1992-03-31 | 1993-10-06 | Laboratoire Europeen De Biotechnologie S.A. | Monoclonal antibodies against the interferon receptor, with neutralizing activity against type I interferon |
US5821078A (en) | 1992-09-03 | 1998-10-13 | Yeda Research And Development Co. Ltd. | Nucleic acid encoding interferon-α/β binding protein |
US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
US5780027A (en) | 1995-07-14 | 1998-07-14 | Meiogen Biotechnology Corporation | Methods of treatment of down syndrome by interferon antagonists |
IL118096A0 (en) | 1996-05-01 | 1996-09-12 | Yeda Res & Dev | Antibodies against interferon alpha/beta receptor |
US6713609B1 (en) | 1996-07-16 | 2004-03-30 | Genentech, Inc. | Monoclonal antibodies to type I interferon receptor |
EP0859633A2 (en) | 1996-08-16 | 1998-08-26 | Kurt B. Osther | Method for treating diabetes |
US5902321A (en) | 1997-07-25 | 1999-05-11 | Innovasive Devices, Inc. | Device and method for delivering a connector for surgically joining and securing flexible tissue repair members |
US20030018174A1 (en) | 1997-10-06 | 2003-01-23 | Genentech, Inc. | Monoclonal antibodies to IFNAR2 |
AU2342900A (en) | 1998-09-23 | 2000-05-01 | Cleveland Clinic Foundation, The | Novel interferon stimulated and repressed genes |
AUPP670698A0 (en) | 1998-10-23 | 1998-11-19 | Monash University | A method of regulation |
KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
JP5007007B2 (ja) | 1999-11-15 | 2012-08-22 | ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 樹状細胞に特異的な抗原結合フラグメント、その組成物および使用方法、それによって認識される抗原およびそれによって得られる細胞 |
GB0001710D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic treatment |
GB0001712D0 (en) | 2000-01-25 | 2000-03-15 | Pharma Pacific Pty Ltd | Therapeutic peptides |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
US6660523B2 (en) | 2000-09-21 | 2003-12-09 | Schering Corporation | Dendritic cells; methods |
EP1351707B9 (en) | 2001-01-09 | 2012-01-25 | Baylor Research Institute | Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays |
DE20100503U1 (de) | 2001-01-12 | 2001-05-10 | Josef Schiele Ohg | Beschichtungsvorrichtung für ein langgestrecktes Werkstück |
US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
FR2822845B1 (fr) | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
JP2006506943A (ja) * | 2002-02-11 | 2006-03-02 | ジェネンテック・インコーポレーテッド | 抗原結合速度の大きい抗体変異体 |
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
KR101329843B1 (ko) | 2002-11-15 | 2013-11-14 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
DK2418220T3 (da) | 2003-12-10 | 2017-11-06 | Squibb & Sons Llc | Interferon-alpha-antistoffer og anvendelser deraf |
WO2006031653A2 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
AU2005291741B2 (en) | 2004-10-07 | 2011-11-24 | Universitat Zurich | Type I interferon blocking agents for prevention and treatment of psoriasis |
US7888481B2 (en) | 2005-02-10 | 2011-02-15 | Baylor Research Institute | Anti-interferon alpha monoclonal antibodies and methods for use |
KR101363120B1 (ko) | 2005-02-10 | 2014-02-13 | 베일러 리서치 인스티튜트 | 항-인터페론 알파 모노클로날 항체 및 사용 방법 |
JP5230022B2 (ja) | 2006-08-09 | 2013-07-10 | ベイラー リサーチ インスティテュート | 抗インターフェロンアルファモノクローナル抗体及び使用方法 |
-
2009
- 2009-05-06 BR BRPI0912570A patent/BRPI0912570B8/pt active IP Right Grant
- 2009-05-06 CN CN200980116496.6A patent/CN102083859B/zh active Active
- 2009-05-06 MX MX2010012052A patent/MX2010012052A/es active IP Right Grant
- 2009-05-06 ES ES09742079.8T patent/ES2549903T3/es active Active
- 2009-05-06 JP JP2011507904A patent/JP5766598B2/ja active Active
- 2009-05-06 CA CA2722622A patent/CA2722622C/en active Active
- 2009-05-06 RU RU2010150105/10A patent/RU2532832C2/ru active
- 2009-05-06 KR KR1020107027445A patent/KR101687032B1/ko active IP Right Grant
- 2009-05-06 WO PCT/EP2009/055448 patent/WO2009135861A2/en active Application Filing
- 2009-05-06 US US12/597,357 patent/US8163885B2/en not_active Expired - Fee Related
- 2009-05-06 EP EP09742079.8A patent/EP2279207B1/en active Active
- 2009-05-06 AU AU2009245792A patent/AU2009245792B2/en active Active
- 2009-05-07 TW TW098115102A patent/TWI453032B/zh active
-
2010
- 2010-10-28 IL IL208979A patent/IL208979B/en active IP Right Grant
- 2010-12-06 ZA ZA2010/08748A patent/ZA201008748B/en unknown
-
2011
- 2011-08-02 HK HK11107983.1A patent/HK1154251A1/zh unknown
-
2012
- 2012-02-01 US US13/363,609 patent/US8361463B2/en active Active
- 2012-12-19 US US13/719,536 patent/US8658771B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP5766598B2 (ja) | 2015-08-19 |
BRPI0912570B8 (pt) | 2021-05-25 |
CA2722622A1 (en) | 2009-11-12 |
ZA201008748B (en) | 2013-02-27 |
US20120195888A1 (en) | 2012-08-02 |
BRPI0912570B1 (pt) | 2021-04-06 |
WO2009135861A2 (en) | 2009-11-12 |
TWI453032B (zh) | 2014-09-21 |
US8658771B2 (en) | 2014-02-25 |
IL208979B (en) | 2018-02-28 |
CN102083859B (zh) | 2014-09-17 |
AU2009245792A1 (en) | 2009-11-12 |
TW200950807A (en) | 2009-12-16 |
US20110213125A1 (en) | 2011-09-01 |
AU2009245792B2 (en) | 2012-11-01 |
JP2011519571A (ja) | 2011-07-14 |
KR101687032B1 (ko) | 2016-12-15 |
EP2279207A2 (en) | 2011-02-02 |
HK1154251A1 (zh) | 2012-04-13 |
EP2279207B1 (en) | 2015-09-09 |
US20130101602A1 (en) | 2013-04-25 |
CA2722622C (en) | 2018-01-02 |
IL208979A0 (en) | 2011-01-31 |
CN102083859A (zh) | 2011-06-01 |
MX2010012052A (es) | 2010-12-14 |
ES2549903T3 (es) | 2015-11-03 |
RU2532832C2 (ru) | 2014-11-10 |
KR20110042264A (ko) | 2011-04-26 |
RU2010150105A (ru) | 2012-06-20 |
US8361463B2 (en) | 2013-01-29 |
WO2009135861A3 (en) | 2010-01-28 |
US8163885B2 (en) | 2012-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0912570A2 (pt) | anticorpos humanizados contra interferon-alfa humano | |
HK1256622A1 (zh) | Il-6的抗體和其用途 | |
LTC2356151I2 (lt) | Didelio afiniškumo žmogaus antikūnai prieš žmogaus IK-4 receptorius | |
IL271270A (en) | Antibodies to 6-il and their use | |
CY2017021I1 (el) | Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9 | |
IL232276A0 (en) | Antibodies to 6-il and their uses | |
BRPI0819205A2 (pt) | Anticorpos humanizados contra tl1a | |
EP2504031A4 (en) | ANTI-IL-6 ANTIBODIES AND THEIR USE | |
ZA201200732B (en) | Fully human antibodies to btla | |
IL196701A0 (en) | HUMAN ANTIBODIES TO ErbB2 | |
IL214779A0 (en) | Fully human antibodies specific to cadm1 | |
BRPI0919062A2 (pt) | anticorpos contra il-25 | |
TH0601001328A (th) | การเสริมการปล่อยสารที่ให้ประโยชน์ของผิวหนัง |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: ARGOS THERAPEUTICS , INC. (US) |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/05/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |